Master the 2022 AHA/ACC/HFSA heart failure guidelines for primary care — ARNI, beta-blocker, MRA, SGLT2i, and new HFpEF therapies including SGLT2 inhibitors and GLP-1 receptor agonists. Earn CME credits.
KDIGO 2024, the four pillars, and the FLOW & CONFIDENCE trials — what primary care needs to do differently for chronic kidney disease.
Chronic Kidney Disease in Primary Care: The Four Pillars of Kidney Protection Read More »
For years, the conversation around GLP-1 receptor agonists in type 2 diabetes centered almost entirely on glucose lowering. Then came a series of landmark cardiovascular outcomes trials — LEADER, SUSTAIN-6, PIONEER 6 — and the paradigm began to shift. But until recently, one practical barrier remained: most GLP-1 receptor agonists required subcutaneous injection, limiting uptake
